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Summary
CD2 is an intercellular adhesion molecule that has been implicated in T cell activation and
differentiation both in humans and mice. Although the ligand for human CD2 has been defined
as LFA-3, that for murine CD2 has not been identified yet. To identify the ligand for mouse
CD2, we generated a chimeric molecule consisting of the extracellular domain of mouse CD2
and human immunoglobulin (Ig)G1 Fc (mCD2Rg) . A hamster monoclonal antibody (mAb),
HM48-1, was established by screening mAbs that could block the binding of mCD2Rg to T
cell lines at the ligand site. The putative mouse CD2 ligand recognizedby this mAb was a glycosyl
phosphatidylinositol-anchored glycoprotein with an apparent molecular mass of 45 W, which
were shared characteristics with human LFA-3. However, its expression was predominantly restricted
to hematopoietic cells, unlike human LFA3. Protein microsequencing analysis for the NH2-
terminal 18 amino acid residues of the affinity-purified HM48-1 antigen revealed that it is almost
identical with mouse CD48. This identity was further confirmed by the reactivity of HM48-1
with a soluble recombinant CD48 (sCD48) protein and the molecule recognized by a rat mAb
raised against sCD48. A rat anti-CD48 mAb blocked the mCD2Rg binding as well as HM48-1.
Moreover, sCD48 also inhibited the mCD2Rg binding to the cellular ligand. Finally, like anti-
CD2 mAb, HM48-1 inhibited the phytohemagglutinin response and, when crosslinked, augmented
the anti-CD3 response of splenic T cells. These results indicate that CD48 is a ligand for mouse
CD2 and is involved in regulating T cell activation.
C
D2 has been implicated in T cell adhesion and activa-
tion (1, 2). A natural ligand for CD2 has been identified
as LFA-3, which is expressed on a variety of cells, including
nonhematopoietic cells in humans (3-5). CD2 and LFA-3
molecules have a structural similarity (6) and a close genetic
linkage (7), suggesting that these molecules have evolved from
a common precursor, which has a homotypic adhesion func-
tion-like neural cell adhesion molecule, by a gene duplica-
tion (8). It has been proposed that the intercellular interac-
tion between CD2 and LFA3 leads to bidirectional signaling
via each molecule, resulting in activation ofboth T cells and
APC (9-11) . However, it has been demonstrated that the
binding of LFA-3 was not sufficient for triggering T cell ac-
tivation via CD2 since the addition of anti-CD2R mAbs was
required (12-14). This suggests the existence of an additional
ligand corresponding to anti-CD2R mAb, but it has not been
identified yet.
CD48, which is known as Blast-1 in humans (15), OX-45
in rats (16), and BCM1 in mice (17), is a glycosyl phosphati-
dylinositol (GPI)t-anchored glycoprotein expressed on al-
most all T and B cells, whose function remains unknown.
Molecular cloning studies revealed a high structural homology
of human CD48 molecule to LFA-3 (18), suggesting that
it would also function as an adhesion molecule. We describe
here that CD48 is a ligand for mouse CD2 and is involved
in regulating T cell activation.
Materials and Methods
Cell Lines.
￿
Mouse T cell leukemia MBL2 was maintained in
RPMI 1640 (Nissui Pharmaceutical Co., Tokyo, Japan) sup-
plemented with 10% heat-inactivated FCS (1R Scientific Inc.,
I Abbreviations used in this paper. GPI, glycosyl phosphatidylinositol;
ICAM-1, intercellular adhesion molecule 1; PI-PLC, phosphatidylinositol
phospholipase C; SF, superfamily.
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2MM L-glutamine, 2.3 mg/ml Hepes, and 2.0 mg/mlNaHCO3 .
Mouse cytotoxic T cell line CTLL2 was cultured in the same
medium supplemented with 50 U/ml of rIL2 (Shionogi Pharmaceu-
tical Co ., Osaka, Japan) .
Antibodies.
￿
RatmAbs reactive with mouse CD2 (RM2-1) (19),
mouse CD48 (MRCOX78) (A . F . Williams, manuscript in prep-
aration), heat-stable antigen (J11d) (20), LFA-1 (KBA) (21), inter-
cellular adhesion molecule 1 (ICAM-1) (KAT 1) (K . Kato, manu-
script in preparation), and hamstermAbs reactive with mouseCD2
(HM2-31), which was raised against affinity-purified mouse CD2
molecule and reacts with aCD2R epitope (H . Yagita, details will
be described elsewhere), and mouse CD3 (145-2C11) (22) were
purified from ascites by using mAb Trap G (Pharmacia, Uppsala,
Sweden) affinity chromatography. FITC-conjugated anti-human
IgG andFITC-conjugated anti-hamster IgG antibodies were pur-
chased from Caltag Laboratories (San Francisco, CA) .
mCD2Rg Construction .
￿
The mouseCD2cDNA (pMCD2-2)
(23) was digested with HpaI, which cleaves the cDNA near the
start ofthetransmembrane region, andadouble-stranded synthetic
oligonucleotide BamHI adaptor:
AACTGTCCAGAGAAG
TTGACAGGTCTCTTCCTAG
regenerating the codons for Asn-Cys-Pro-Glu-Lys was ligated to
the blunt HpaI ends . After EcoRI digestion, the 650-bp EcoRI-
BamHIfragment containing the extracellular region of mouse CD2
cDNA and the 1.3-kb BamHI-XbaI fragment containing human
IgG1 constant region genomic sequences, whichwas prepared from
an -IgG1 expression plasmid provided by Dr. Brian Seed (Mas-
sachusetts General Hospital, Boston, MA) (24), were subcloned
into EcoRI- and XbaI-digested pBluescript II SK(+) vector
(Stratagene, La Jolla, CA) . This results in the in-frame fusion of
mouse CD2 extracellular region to the human IgG1 hinge region
as shown in Fig . 1A . After digestion with XhoI and NotI, a 1.95-
kb insert containing the fusion construct was transferred into the
XhoI and Nod sites of the BCMGSneo expression vector (25),
kindly provided by Dr. H. Karasuyama (Basel Institute, Basel, Swit-
zerland) .
Preparation ofmCD2Rg Chimeric Protein .
￿
Mouse myeloma cell
line P3U1 was transfected with mCD2Rg cDNA in the expres-
sion vectorBCMGSneo by using a Cell-Porator (Bethesda Research
Laboratories, Gaithersburg, MD). Transfected cells were selected
using 1 mg/ml of G418 (Geneticin ; Wako Pure Chemical Indus-
tries, Osaka, Japan) and analyzed for cytoplasmic expression of the
mCD2Rg protein by immunofluorescence assay using FITC-
conjugated anti-human IgG . After cloning by limiting dilution,
secretion of the mCD2Rg chimeric protein into the medium was
detected by immunoprecipitation, andthe reactivity ofmCD2Rg
against mouse cell lines was tested by immunofluorescence assay
as follows.
Immunofluorescence Assay.
￿
To examine the reactivity ofmCD2Rg
against mouse cell lines, the pellets of 106 cells were incubated
with 1 ml of culture supernatant containing mCD2Rg for 1 h at
4°Cfollowed by FITC-conjugated anti-human IgG. After gently
washing, the cells were analyzed on a FACScan® (Becton Dick-
inson & Co ., San Jose, CA) and data were processed by using the
Consort 30 program .
Immunoprecipitation . The mCD2Rg transfectants (106) were
cultured with 100 ACi/ml [35S]-Met and [3'S]-Cys (TransLabel;
ICN Biomedicals Inc., Costa Mesa, CA) at 37°C for 16 h. The
culture supernatant wasimmunoprecipitated with protein G-con-
jugated Sepharose (Pharmacia) or anti-mouseCD2mAb(RM2-1)-
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coupled Sepharose for 1 h at 4°C . Afterwashing with 1% NP-40
in PBS, the bound materials were eluted and subjected to SDS-
PAGE analysis under nonreducing or reducing conditions . For
fluorography, gels were incubated with Amplify (Amersham Japan,
Tokyo, Japan) for30 min, dried, and exposed to x-ray film (Kodak
XAR-5) at -80°C for 24 h. .
To identify theHM48-1-recognizedantigenon mouse cell lines,
cell pellets (107) were suspended in saline containing 0.1M Hepes,
and then labeled with 100 lag/ml of sulfo-N-hydroxysuccinimide-
biotin (Pierce Chemical Co., Rockford, IL) for 40 min at room
temperature . Biotin-labeled cells were extracted with a lysis buffer
(1% NP-40, 20 mM Tris-HCI, 150 mM NaCl, 2 mM CaC12, 2
mm MgC1 2 , 10 AM A-PMSF, and 50 Eag/ml trypsin inhibitor) .
After preclearing with normal hamster Ig-coupled Sepharose, the
lysate was immunoprecipitated with HM48-1-coupled Sepharose
for 1 h at 4°C. After washing with the lysis buffer, the eluates
were subjected to SDS-PAGE and electroblotted onto nitrocellu-
lose membrane filters (Nihon Millipore KogyoK.K ., Japan) . The
blots were subsequently incubated with VECTASTAIN ABC so-
lution (Vector Laboratories Inc., Burlingame, CA) . After washing,
the blots were further incubated with ECL Western blotting de-
tection reagents (AmershamJapan) and exposed to x-ray films for
a few minutes .
Generation ofmAb .
￿
Male Armenian hamsters (Kyokuto Phar-
maceutical Industrial Co ., Tokyo, Japan) were immunized by in-
traperitoneal injection of mouse T lymphoma MBL2 (107) for sev-
eral times at 10-d intervals . 3 d after final immunization, the
splenorytes were prepared and fused with PA-I mouse myeloma
cells as described previously (19) . After HAT selection, the anti-
bodies that inhibit the binding of mCD2Rg to MBL2 were
screened . HM48-1 was identified by its strong inhibitory effect and
cloned by limiting dilution .
InbredAO rats(MRC Cellular Immunology Unit, Oxford, UK)
were immunized twice subcutaneously with 20-100 AgsCD48 (17)
in CFA within a 2-wk interval . The rats were boosted with 20
Ag sCD48 intravenously 4 d before fusion . The splenorytes were
prepared by teasing the spleen in RPM1 1640 and were fusedwith
parental Y3 myeloma cells at a ratio of 2:1 in 1 .2 ml50% polyeth-
ylene glycol 4000 in HBSS . The cell mixture was resuspended in
25 ml Isocove's medium with 20% FCS and HAT, and dispensed
into a 96-well plate . The culture supernatants were screened by
binding assay with BALB/c thymocytes and 12sI-labeled rabbit
anti-rat Fab, and the positive clones were further cloned by lim-
iting dilution analysis . Theantibody isotype of the clones was de-
termined with an isotyping kit (Serotec Ltd., Kidlington, Oxford,
UK) .
Affinity Purification of the HM48-1 Antigen and Protein Microse-
quencing. The lysate prepared from 10 1° MBL2 cells in the same
lysis buffer as used in immunoprecipitation was subjected to 1 ml
of HM48-1-conjugated Sepharose. After washing with the lysis
buffer, thebound material was eluted with 50 mM glycine buffer
(pH 3.0) containing 0.1% NP-40 . 900-Al fractions were collected
and immediately neutralized with 1MTris buffer (pH 7.8) . 10-ILI
aliquots of each fraction were subjected to SDS-PAGE and silver
staining. The fractions containing the antigen were pooled, dia-
lyzed against distilled water, and lyophilized . Approximately 10
Ag of the affinity-purified antigen was subjected to a 4-20% gra-
dient SDS-PAGE, electroblotted onto a polyvinylidine difluoride
membrane (Applied Biosystems, Inc ., Foster City, CA), and stained
with coomassie blue. Theband wascut outand subjected to microse-
quencing on a sequencer equipped with on-linePTH analysis (477A ;
Applied Biosystems, Inc.) .
Phosphatidylinositol Phospholipase C (PI-PLC) Treatment .
￿
Spleencells (106/ml) were incubated in serum-free RPMI 1640 with or
without 50mU/ml ofPI-PLC (Boehringer Mannheim, Mannheim,
Germany) for 60 min at 37°C . After washing three times with
the medium, the reactivity with HM48-1 andJ11d was analyzed
by immunofluorescence .
Proliferation Assay .
￿
Spleen cells were cultured with 1 Wg/ml of
ConA(Sigma ChemicalCo., St . Louis, MO)or 10 AA/ml ofPHA
(Difco Laboratories, Detroit, MI) at 37°C in the presence or ab-
sence ofvariousmAbs (10 jig/ml) for 48 h . The cultures were pulsed
with 1 PCi ['H]TdR for the last 4 h. Cells were collected by using
a cell harvester (Skatron, Lier, Norway), and the radioactivity of
each well wasmeasured by a standard liquid scintillation counting .
To examine a stimulatory effect of mAbs, nylon wool-nonad-
herent spleen cells were cultured with 1 t~g/ml ofanti-CD3 mAb
(145-2C11) in the presence or absence ofHM2-31 or HM48-1 mAbs
on anti-hamster IgG-coated plates for 48 h, and the incorporation
of [3H]TdR was measured as above .
Results
Construction and Characterization ofmCD2Rg Chimeric Pro-
tein. The construction of the mCD2Rg chimeric protein
was depicted in Fig. 1A . ThemCD2Rg construct was sub-
cloned into the mammalian expression vector BCMGSneo
andintroduced into the myeloma cell lineP3U1 by electropo-
ration . Transfected cells were selected by G418 and cloned
by limiting dilution . To determine the secretion ofmCD2Rg
protein into the culture supernatant of the transfectants, we
performed immunoprecipitation with RM2-1 (anti-mouse
CD2 mAb)-conjugated Sepharose andprotein G-conjugated
Sepharose. As shown in Fig. 1 B, a single polypeptide with
an apparent molecular mass of 180kD was immunoprecipi-
tated by both RM2-1 and protein G from the supernatant
of mCD2Rg transfectants under nonreducing conditions .
After reduction, a single band of 80 kD was detected in the
immunoprecipitates, indicating that themCD2Rg chimeric
protein was expressed as a disulfide-linked homodimeric
molecule.
Generation ofHM48-1 mAh Which InhibitsmCD2Rg Binding
to Mouse TCells. We first estimated thebinding ofmCD2Rg
to various mouse cell lines by immunofluorescent staining
with FITC-conjugatedanti-human IgGand flow cytometric
analysis. ThemCD2Rg bound to severalT cell lines, including
CTLL2, MBL2, and FBL3. The binding of mCD2Rg to
CTLL2 was completely abrogated by preincubation with
RM2-1 (Fig . 2 A) but not with anti-LFA-1 or anti-ICAM-1
mAbs of the same isotype (data not shown), indicating that
themCD2Rg bindingwasCD2 dependent . To generate the
mAbs that inhibit themCD2Rg binding at the ligand site
on the cells, we immunizedArmenian hamsters withMBL2,
and the resulting immune splenocytes were fusedwith PA-1
myeloma. After screening the ability to inhibit themCD2Rg
binding and cloning, we established amAb HM48-1 (ham-
ster IgG) that couldcompletely block thebindingofmCD2Rg
to MBL2 andCTLL2 (Fig . 2 B) . HM48-1 exhibited an in-
hibitory effect even when the cells were preincubated with
it andwashed before estimating themCD2Rg binding, sug-
gesting that this mAb recognizes a ligand for mouse CD2.
A similar pretreatment ofthe cellswith anti-CD2, anti-LFA 1, .
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Figure 1 .
￿
Constructionand characterization ofmCD2Rg chimeric pro-
tein. (A) Schematic representation ofmCD2Rg construction. cDNA en-
coding the extracellular region of mouseCD2(mCD2ex) was fused with
genomic humanCyl (hC-yl) gene-containingexons for hinge (H), CH2,
and CH3 regions . (B) Immunoprecipitation of radiolabeled mCD2Rg .
Expression plasmid containing the chimeric constructwas transfected into
P3U1 myeloma cells. mCD2Rg transfectants (mCD2Rg-P3U1 ; lanes 1,
2, 5, and 6) and parent cells (P3U1 ; lanes 3, 4, 7, and 8) were labeled
with [35S]Met and [35S]Cys, and the labeled proteins secreted into culture
supernatants were immunoprecipitated with protein G-Sepharose (lanes
1, 3, 5, and 7) or anti-mouse CD2mAb-conjugated Sepharose (lanes 2,
4, 6, and 8) . Theprecipitates were subjected to SDS-PAGE (4-20%) under
nonreducing (NR; lanes 1-4) or reducing (R ; lanes 5-8) conditions and
then to fluorography . Position of the molecularmass markers are indicated
on the left .
or anti-ICAM-1 mAbs did not affect themCD2Rg binding
(data not shown) .
Cell Surface Expression ofthe Antigen Recognized by HM48-1 .
We next examined the distribution of the HM48-1-defined
Ag on various mouse cells . HM48-1 reacted not only with
CTLL2 andMBL2 but also with all spleen cells and thymo-
cytes (Fig . 3 A) . The Ag defined by HM48-1 was widely
distributed in hematopoietic cell lines, including helper T
cell lines, cytotoxic T cell lines, T and B lymphomas, and
macrophages, but not in nonhematopoietic cell lines, including
fibroblasts, carcinomas, and melanomas (data not shown) .
We next examined the biochemical nature of the HM48-
1-defined Ag on lymphocytesby using the enzyme PI-PLC,
which cleaves the GPI-anchored membrane proteins, including
human LFA-3 (26) and mouse heat-stable antigen (27) . TheE
z
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Figure 2 .
￿
Binding ability ofmCD2Rg chimeric protein . (A) Inhibi-
tory effect of RM2-1 on mCD2Rg binding. Mouse T cell line CTLL2
was stained with mCD2Rg chimeric protein in the presence or absence
of RM2-1 at 10 p,g/ml, followed by FITC-conjugated anti-human IgG
antibody. (B) Inhibitory effect ofHM48-1 onmCD2Rg binding .CTLL2
was first pretreated with HM48-1 at 101~g/ml . After washing with PBS,
the cells were stained withmCD2Rg and FITC-conjugated anti-human
IgG. A total of 10,000 cells each was analyzed on FACScans .
treatment of spleen cells with PI-PLC resulted in a marked
decrease in binding of HM48-1 and J11d as determined by
indirect immunofluorescence (Fig . 3 B) . This decrease was
specific for theHM48-1Ag and was not observed with CD2,
which possesses a cytoplasmic tail (data not shown) . These
results indicate that the HM48-1-defined Ag is a GPI-anchored
membrane molecule, which is a shared characteristic with
human LFA-3 .
J11d
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Figure 3 .
￿
Expression and PI-PLC sensitivity of the HM48-1-defined an-
tigen on mouse thymocytes and splenocytes . (A) Reactivity of HM48-1
with mouse thymocytes (THY) and splenocytes (SPL) . Cells were stained
with HM48-1 at 10 pg/ml, followed by FITC-conjugated anti-hamster
IgG. (B) Effect of PI-PLC treatment on HM48-1 reactivity. Splenocytes
were treated with PI-PLC (thin lines) and then stained with J11d (left) or
HM48-1 (right). FITC-conjugated anti-rat IgG or FITC-conjugated
anti-hamster IgG were used as second-step reagents forJ11d and HM48-1,
respectively. Solid lines indicate splenocytes treated with the medium
without PI-PLC . Dotted lines indicate the staining with second-step re-
agents alone .
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Molecular Characterization of the HM48-1-defined Ag .
￿
Bio-
chemical natures ofthe HM48-1-defined Ag were further ex-
amined by immunoprecipitation and SDS-PAGE analysis. Ly-
sates of surface biotinylatedMBL2, CTLL2, thymocytes, and
splenocytes were subjected to immunoprecipitation with
HM48-1-conjugated Sepharose, and SDS-PAGE analysis was
performed under nonreducing or reducing conditions. As
shown in Fig. 4 A, the Ag defined by HM48-1 was a single
polypeptide with apparent molecular masses of 45 or 50 kD
under nonreducing or reducing conditions, respectively . A
similar molecule was also identified from CTLL2, thymo-
cytes, and spleen cells (Fig. 4 B) .
We next performed the affinity purification of theHM48-
1-defined Ag. Detergent lysate ofMBL2 T lymphoma cells
(1010) was subjected to the HM48-1-coupled Sepharose col-
umn, and the bound proteins were eluted and fractionated .
As shown in Fig . 5 A, three fractions containing the 45-kD
molecule were pooled and subjected to protein micro-
sequencing. The NH 2-terminal 18-amino acid residues were
determined, except for one residue, which was obscure and
indicated with anX in Fig . 5 B . We performed a computer
search for the protein data base and unexpectedly found an
extremely high homology to mouse CD48 rather than human
LFA-3 . In Fig. 5 B, the NH2-terminal sequences of the
HM48-1 Ag, mouse, rat, or humanCD48 (16-18), andhuman
LFA3 (6) are aligned . 16 of 18 NH2-terminal residues of the
HM48-1-definedAg were identical with that of mouse CD48 .
The obscurity of residue 16 of the HM48-1 Ag might result
Figure 4 .
￿
Immunoprecipitation ofthe antigen recognized by HM48-1 .
(A) MBL2 mouse T lymphoma cells (10 7) were surface biotinylated and
lysed in lysis buffer containing 1% NP-40 . Immunoprecipitation was per-
formed by using normal hamster serum (NHS; lanes 2 and 4) or HM48-1
(lanes 1 and 3) . Eluates were subjected to SDS-PAGE (4-20%) under
reducing (R ; lanes 1 and 2) or nonreducing (NR ; lanes 3 and 4) condi-
tions and then blotted onto nitrocellulose membranes . Biotinylated pro-
teins were detected byABC complex and chemiluminescence . (B)CTLL2
mouse T cell line (10 7 ), mouse Spenocytes (2 x 108 ), and thymocytes
(2 x 108 ) were surface biotinylated and lysed . Immunoprecipitates with
HM48-1 were subjected to SDS-PAGE under reducing (R ; lanes 1-3) or
nomeducing(NR ; lanes 4-6) conditions and then to blotting. Biotinylated
proteins were detected as above. Positions of the molecular mass markers
are indicated on the left .from its potential N-glycosylation . In contrast, no similarity
was observed between the HM48-1-defined Ag and human
LFA-3 . These results strongly suggested that the HM48-1
Ag is not a mouse homologue ofhuman LFA-3 but of mouse
CD48 .
HM48-1 Reacts with Mouse CD48.
￿
To conclude whether
HM48-1 is directed to mouse CD48, sequential immuno-
precipitation was carried out by using HM48-1 and a rat
anti-mouse CD48 mAb, MRC OX78, which was prepared
against a soluble recombinant mouse CD48 protein (A . F.
Williams, manuscript in preparation) . HM48-1 immunopre-
cipitated a molecule the same size as that precipitated byOX78
from the surface-biotinylated MBL2 lysate (Fig. 6) . After
preclearing with OX78 mAb, the 45-kD HM48-1 Ag disap-
peared . This result indicates that HM48-1 and OX78 do react
with the same molecule. Moreover, HM48-1 reacted with
the soluble recombinant mouse CD48 (sCD48) protein (17)
in ELISA and Western blotting (data not shown) . These results
definitively indicated that HM48-1 is directed to mouse CD48.
sCD48 Protein and Anti-CD48 mAbs Block the mCD2Rg
Binding . To confirm that mouse CD48 recognized by HM48-1
is a ligand formouseCD2, we examined the inhibitory effects
of sCD48 protein (17) and the rat anti-mouse CD48 mAb
(0X78) on the mCD2Rg binding to MBL2 . As shown in
Fig. 7 A, pretreatment of MBL2 with OX78 as well as
HM48-1 could have completely inhibited the mCD2Rg
binding . Furthermore, preincubation of mCD2Rg with
sCD48 perfectly abrogated its binding ability toMBL2 (Fig.
7 B) . These results clearly indicated that mouse CD48 acts
as the ligand for mouse CD2 .
Mouse CD48 Is Involved in T Cell Activation .
￿
We finally
performed preliminary studies on the biological functions of
mouse CD48 by using HM48-1 mAb . We previously ob-
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Figure 5 .
￿
Affinity purification of the
HM48-1 Ag and comparison of its NHz-
terminal sequence with CD48 and LFA-3 .
(A) The lysate ofMBL2 (10 1°) was sub-
jected to HM48-1 conjugated Sepharose.
After washing with lysis buffer, the bound
materials were eluted with glycinebuffer.
10yrl aliquots of each fraction were sub-
jected to SDS-PAGE and silver staining .
Thearrow indicates the HM48-1 antigen .
The fractions containing the antigen were
pooled and subjected to protein microse-
quencing . (B) N112-terminal amino acid
sequence of the HM48-1 antigen, those
ofmouse, rat, or human CD48, and that
ofhuman LFA-3 are aligned . Identical re-
sidues with the HM48-1 antigen are
boxed. The asterisk above residue 16 in-
dicates the potential N-glycosylation site
of mouse CD48 .
served that PHA, but not Con A, response ofmouse spleen
cells was highly susceptible to anti-CD2mAb (28) . HM48-1
exhibited a similar inhibitory effect to that ofRM2-1 onPHA
and Con A responses (Fig . 8) . The addition of both RM2-1
and HM48-1 exhibited a similar extent of inhibition as those
observed with each mAb alone (data not shown), suggesting
that CD2 and CD48 act as a receptor ligand pair involved
in PHA response.
It was ofinterest to study whether mouseCD48 itselfwould
Figure 6 .
￿
Sequential immunoprecipitation of the antigen recognized
by HM48-1 and MRC OX78 . NP-40 1ysate ofsurfacebiotinylated CTLL2
(107) was precleared with normal hamster serum (NHS; lanes 1-3) or
mAb reactive with murine CD48 (0X78 ; lanes 4-6) . The precleared
lysates were then subjected to immunoprecipitation with NHS (lanes 1
and 4), HM48-1 (lanes 2 and 5), or OX78 (lanes 3 and 6) as described
in Fig. 4 . SDS-PAGE was performed under nonreducing conditions .
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Figure 7 .
￿
Inhibitory effects of a rat anti-mouse CD48 mAb and sCD48
on mCD2Rg binding . (A) CTLL2 was first pretreated with HM48-1,
0X78, or RM2-1, as indicated . After washing with PBS, the cells were
stained with mCD2Rg and FITC-conjugated anti-human IgG antibody.
(B) CTLL2 was stained withmCD2Rg in thepresence or absence of sCD48
(50 ug/ml), followed by FITC-conjugated anti-human IgG. A total of
10,000 cells each was analyzed on FACScan® .
be involved in T cell activation, since some GPI-anchored
T cell surface molecules, including Thy-1 and Ly6, have been
implicated in T cell activation (29-31) . Although HM48-1
alone did not induce the proliferative response of splenic T
cells even when crosslinked with anti-hamster IgG antibody
(data not shown), it was shown that HM48-1 greatly aug-
mented the proliferative response when cocrosslinked with
an anti-CD3 mAb (Fig. 9) . A similar costimulatory effect
was also observed with an anti-CD2R mAb (HM2-31) . These
results indicate that CD48 can also act as a signal-transducing
molecule regulating the CD3-mediating T cell activation as
well as CD2 .
In the present study, we generated amAb against the mouse
CD2 ligand by screeningmAbs that could inhibit the binding
of amouse C132-human Ig fusion protein . Surprisingly, the
Ag recognized by this mAb was not a mouse homologue
ofhuman LFA-3 but was mouse CD48 . The fact that CD48
is a ligand for mouse CD2 was further confirmed by using
an authentic anti-CD48 mAb and sCD48 protein . In addi-
tion, we finally indicated that CD48 is involved in mouse
T cell activation like CD2 .
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Figure 9 .
￿
Costimulatory effect ofHM48-1 on anti-CD3 response. Nylon
wool-nonadherent spleen cells were cultured with anti-CD3 mAb (145-
2C11 ; 1 pg/ml) in the presence or absence ofnormal hamster IgG (NHIgG),
anti-CD48 mAb (HM48-1), or anti-CD2 mAb (HM2-31) at 10 pg/ml
on anti-hamster IgG-coated plates for 48 h . The incorporation of
[3H]TdR was measured as described in Fig . 8 . Data represent means ±
SD or triplicate wells .
To identify the mouse CD2 ligand, we first constructed
a chimeric protein consisting of the extracellular region of
mouse CD2 and the human IgG1 constant region. This
mCD2Rg bound to severalT and B cell lines but not to non-
hematopoietic cell lines . The binding ofmCD2Rg was in-
hibited by anti-CD2 mAb but not by anti-LFA-1 or anti-
ICAM-1 mAbs of the same isotype, indicating that it was
CD2 dependent . Our findings with mCD2Rg are consis-
tent with the results recently reported by Rutschmann and
Karjalainen (32) . They also pointed out a preferential expres-
sion of the mouse CD2 ligand on lymphoid cells by using
a mouse C132-human C lu fusion protein, although they did
not identify the ligand. These observations are quite different
from the distribution ofhuman LFA-3, which is broadly ex-
pressed on various hematopoietic and nonhematopoietic cells
(33) . To identify the mouse CD2 ligand, we established a
mAb that could interfere with the mCD2Rg binding at the
ligand site. mAb HM48-1 completely inhibited themCD2Rg
binding when preincubated with the target cells. As far as
Figure 8 . Blocking effect of
HM48-1 on PHA and Con A re-
sponses. Mouse splenocytes (5 x
105) were cultured with 10 l~g/ml
of PHA (left) or 1 jug/ml of Con
A (right) in the presence or absence
of the indicatedmAb (10 ug/ml) for
48 h. The cultures were pulsed with
[3H]TdR for the last 4 h, and in-
corporation of [ 3H]TdR was deter-
mined by scintillation counting.
Results are shown as means ± SD
of triplicate wells.we tested, all cell lines that bound mCD2Rg expressed the
HM48-1-defined Ag, and the binding of mCD2Rg to these
cells was always completely blocked by HM48-1. These results
indicate that the Ag recognized by HM48-1 is the predomi-
nant (or apparently sole) ligand for mouse CD2.
We next performed biochemical characterizations of the
HM48-1 Ag to identify whether it is mouse LFA3 or not .
In immunoprecipitation experiments, the Ag's have an ap-
parent molecular mass of 45 and 50 kD under nonreducing
or reducing conditions, respectively. The PI-PLC treatment
abolished the HM48-1 reactivity, indicating that the Ag is
a GPI-anchored membrane protein. These characteristics were
shared with human LFA3. Surprisingly, however, the NH2-
terminal amino acid sequence of the affinity-purified HM48-1
Ag was almost identical to that of mouse CD48, but was
totally different from human LFA-3 . In addition, the results
obtained by using an authentic anti-CD48 mAb and sCD48
protein indicated that HM48-1 does react with mouse CD48.
Furthermore, sCD48 protein as well as another anti-CD48
mAb could inhibit the mCD2Rg binding like HM48-1. Based
on these results, we concluded that CD48 is the predomi-
nant ligand for mouse CD2 .
Human CD48 (Blast-1) was first identifiedas a cell surface
molecule highly expressed on EBVtransformed B lympho-
blasts (34). Further studies indicated that CD48 is a GPI-
anchored membrane protein and is expressed not only on ac-
tivated B cells but also on T cells, monocytes, and endothelial
cells (35) . However, little has been known about the func-
tion of CD48. Molecular cloning studies revealed a struc-
tural and evolutionary relationship of CD48 with LFA3 and
CD2 (16-18). CD48 contains two Ig superfamily (IgSF) do-
mains with the first being Vlike without a disulfide bond,
and the second being a C2-SET domain. This is a shared prop-
erty with CD2 and LFA-3. Notably, the similarity between
the NH2-terminal domains of CD48 and LFA-3 scored 63%
when considering conservative amino acid substitutions (18).
Basedon these observations, CD48 has been proposed to con-
stitute a subgroup within the IgSF along with CD2 and
LFA-3, which is closely related in evolution and suspected
to have evolved from a common precursor (16, 17). This, in
turn, implied that CD48 might function as an adhesion mol-
ecule like LFA-3 and CD2 (18). Recently, Yokoyama et al.
(15) proposed that human CD48 might interact with CD2,
but they did not exhibit any evidence for this interaction.
Therefore, this is the first study indicating the function of
CD48 as a CD2 ligand. In our preliminary studies with
CD2-Ig fusion proteins containing the extracellular portion
of human or rat CD2, it has been observed that CD48 acts
as a CD2 ligand also in humans and in rats (unpublished ob-
servations). Therefore, the interaction between CD48 and
CD2 appears to be conserved among these three species.
In mice and rats, at present, nothing is known about the
human LFA3 homologue. Our repeated trials for genomic
or cDNA cloning of mouse and rat LFA-3 by crosshybridiza-
tion with the human LFA3 cDNA probe were so far unsuc-
cessful. Our present observations that HM48-1 always com-
pletely blocked the mCD2Rg binding to all cells tested suggest
a possibility that LFA3 may not be expressed in mice. The
1247
￿
Kato et al.
gene for human CD48 and those for human CD2 and LFA-3
have been mapped in the pericentric regions of human chro-
mosome 1 in the lg21-23 and lp12 regions, respectively (7,
18, 36) . In mice, the CD48 gene is located in a region of
distal chromosome 1 (17) that is syntenic with human chro-
mosome lg21-32 (37), and the CD2 locus is located in a re-
gion of chromosome 3 (38) that is syntenic with the human
lp12 region (39, 40). In our previous study (17), it has been
suggested that the duplication of a chromosomal region in-
cluding the precursors of the genes for CD48, CD2, and LFA-3
has occurred and the duplicated regions have stayed together
on chromosome 1 in humans with the insertion of a centro-
mere, while, in mice, the genetic regions have become dis-
persed in the formation of chromosomes 1 and 3 . If LFA-3
was not present in mice, it might mean that CD2 and CD48
first evolved from the common precursor before their genetic
regions dispersed in mice, and LFA-3 evolved from CD48
later in humans by a further gene duplication in chromo-
some 1. This speculation is consistent with the fact that CD48
and LFA-3 are more similar in sequence than CD2 and LFA-3.
Such a case, that more members constituting an IgSF sub-
group have evolved from a common precursor in humans than
in mice, has been known for the low affinity Fcy receptors,
for which five genes (hFcyRIIA, hFcyRIIB, hFcyRIIC,
hFcyRIIIAcx, and hFcyRIIIB) have been found in humans
while only two genes (mFcyRII and mFcyRIIIci) have been
found in mice (41). Therefore, CD48 might be the primary
ligand for CD2 commonly used in all mammalian species.
However, it has been demonstrated that the genomic organi-
zation of a set ofmarkers defining the region around the CD2
gene locus on human chromosome lp and on mouse chro-
mosome 3 is highly conserved between these two species (17).
This suggests that the murine LFA-3 gene might be located
near the CD2 gene locus, as is the human LFA-3 gene. Fur-
ther genetic studies will be needed to clarify this issue.
Alternatively, our failure to find another ligand for CD2
might be due to a loweraffinity of mCD2Rg to murine LFA3
than to CD48. However, it seems unlikely since a human
CD2-Ig chimeric protein (hCD2Rg), which was constructed
in a similar way to mCD2Rg, exhibited an almost equiva-
lent affinity to CD48 and LFA-3 (our unpublished obser-
vation).
Several GPI-anchored membrane molecules, including Thy-1
(30), Ly6 (31), and sgp-60 (42, 43), have been implicated in
T cell activation. Therefore, it was of particular interest to
investigate the function of CD48 not only as a CD2 ligand
but also as a potential T cell-activating molecule. We first
examined the effect ofHM48-1 on mitogen responses ofmouse
T cells in order to estimate the involvement of CD48 as a
ligand of CD2. As shown in Fig. 8, HM48-1 strongly in-
hibited the proliferative response to PHA, while the Con A
response was not significantly affected. This paralleled the
effect of RM2-1, suggesting that CD48 would act as the CD2
ligand in the PHA response.
We next demonstrated that the crosslinking of CD48 would
deliver a costimulatory signal augmenting T cell activation.
A synergistic proliferative response was observed when CD48
was cocrosslinked with CD3. A similar costimulatory effectwas also observed when CD2 was cocrosslinked with CD3 .
These results suggest that both the intercellular interaction
between CD2 on a T cell and CD48 on an opposite cell,
and that between CD48 on aT cell andCD2 on an opposite
cell, canbe costimulatory forT cell activation and that CD48
acts as afunctional counter-receptor regulatingT cell activa-
tion . TheTT andTB cell interactions are critically involved
in eliciting and regulating cellular and humoral immune re-
sponses . CD48 is expressed on both T and B cells in mice
(this study) and humans (15), and CD2 is expressed on B
cells in mice in addition to T cells (19) . Although the in-
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